NICE Recommends Against Fludarabine For First-Line Treatment Of CLL
This article was originally published in The Pink Sheet Daily
Executive Summary
Final Appraisal Determination concludes that Fludara monotherapy is not cost effective compared to chlorambucil.
You may also be interested in...
Xanthus Will Develop Oral Fludarabine For U.S. Market
Schering AG opts to out-license the oncologic rather than invest in further clinical study to support U.S. approval of the new dosage form.
Merck KgaA Steps Aside For Bayer/Schering Merger To Move Forward
Bayer will buy Merck’s shares in Schering AG at €89 per share, or €3 more than the current bid.
Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: